ophthalmology News
-
Haymarket Medical Network Launches Ophthalmology Advisor
Haymarket Medical Network today launched Ophthalmology Advisor, a new digital resource that empowers ophthalmology healthcare professionals with comprehensive clinical, surgical, and pharmaceutical information. Ophthalmology Advisor meets the informational and educational needs of ophthalmology specialists by offering the same timely and high quality information that clinicians have come to ...
-
Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures ...
-
Sterile Adjustable Eye Speculum
Sterile Adjustable Eye Speculum (Art.No. SUH04) For temporal and nasal use, with closed blades, Single use, 6 pcs /box. „The new single use eye speculum with closed valves serves very well for the anterior as well as for combined posterior surgery. The speculum is for temporal and nasal use and the lid opening can be easily adjusted. In comparison to the reusable specula, it is ...
-
UNITY Biotechnology to Participate in the UBS 2022 Global Healthcare Conference
UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and participate in one-on-one investor meetings at the UBS 2022 Global Healthcare Conference taking place virtually on Wednesday, May 25th, 2022, at 11:30 AM ET. The ...
-
EyeYon Medical’s Q3/20 Newsletter
Vision accessibility for anyone, anywhere Ready for use, Artificial Endothelial Layer EndoArt® aims to eliminate the need for donor tissue in corneal edema treatment. All you wanted to know about the disruptive EndoArt® Artificial Endothelial Layer at one publication! Take a look at this exciting article with the latest, most updated results of our First in Human trial, already ...
-
PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors
Melbourne, Australia - 30 October 2020: PolyActiva Pty Ltd, a clinical-stage ophthalmology biopharmaceutical company, today announced the appointment of highly experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company's Board of Directors. Ms Valorie is recognized in the industry for her success in building and leading high performing teams and for her ability to lead ...
-
Injectsense adds experts to Medical advisory board
Injectsense, Inc. an innovative medical device firm that develops sensor-enabled digital health systems to measure therapy effectiveness, announced today additional members of its medical advisory board. The board, which includes world renowned specialists and surgeons in the ophthalmic field, provides valuable feedback on device requirements, procedures, risk mitigation, and regulatory issues. ...
-
UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and participate in one-on-one investor meetings at the Cowen 42nd Annual Health Care Conference taking place virtually on Monday, March 7, 2022, at ...
-
Injectsense Demonstrates Animal To Cloud Iop Sensing Pathway
Injectsense, a sensor-enabled digital health company, today announced completion of a successful in-vivo animal study of the first implantable sensor and monitoring system designed to collect long-term intraocular pressure (IOP) data. The Injectsense IOP-Connect system creates an organ-to-cloud data connection that enables the clinician to assess glaucoma therapy effectiveness at any time. The ...
-
Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting
ARLINGTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present data from a previously completed Phase 1b clinical trial of KPI-012 in a poster session at the 2022 Association ...
-
UNITY Biotechnology Announces Restructuring to Advance Corporate Strategy and Focus on Key Ophthalmology Programs
Strategic realignment to focus capital resources on clinical programs and extend cash runway into Q1 2023 12-week data from Phase 2a study of UBX1325 in diabetic macular edema (DME) expected mid-2022 16-week data from Phase 2 study in wet age-related macular degeneration (wet AMD) expected in Q4 2022 UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company ...
-
Ikarovec presents at ARVO 2022 conference
Ikarovec scientific team presented three poster and one oral communication at the Denver Association for Research in Vision and Ophthalmology (ARVO) conference, between 1st and 4th May 2022. The team showcased the four lead programmes and highlighted significant progress towards identifying candidate gene constructs for diabetic macular oedema, wet-form, neovascular age-related macular ...
By Ikarovec
-
Atia Vision Announces Upcoming Presentations Highlighting Modular Presbyopia-Correcting Intraocular Lens Technology
CAMPBELL, CA – September 11, 2019 – Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a novel modular presbyopia- correcting intraocular lens (IOL), today announced its technology will be featured in presentations at two ophthalmology conferences this week in Paris, France. The first presentation will be delivered by ...
-
LayerBio to Present Preclinical Results for Extended Release Glaucoma Formulation at ARVO
LayerBio will present preclinical study results at the Association for Research in Vision and Ophthalmology in Honolulu, Hawaii on Monday, April 30. These results demonstrate the therapeutic potential of its novel extended-release travoprost formulation using LayerBio's proprietary PolyNet delivery technology. LayerBio will present preclinical study results at the Association for Research in ...
-
iSTAR Medical to attend the 34th International Congress of German Ophthalmic Surgeons (DOC)
We will be in Nuremberg next week at the DOC congress where Prof. Dr med. Marc Schargus (Asklepios Klinik Nord, Hamburg) will be presenting a meta-analysis from the STAR-I, STAR-II and STAR-III trials on patients with open-angle glaucoma who consistently achieve low diurnal intraocular pressures (IOP) of ≤18 mmHg up to two-years after implantation with MINIject. The Advanced Glaucoma ...
-
iSTAR Medical appoints leading glaucoma specialist Prof. Kaweh Mansouri as Chief Medical Officer
WAVRE, Belgium — 6 September 2022: iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announces the appointment of Dr Kaweh Mansouri as Chief Medical Officer (CMO). Dr Mansouri is a medical and surgical eye specialist, sub-specializing in glaucoma and cataract. Currently a Consultant Ophthalmologist at the Glaucoma Center, Swiss Visio, ...
-
Metrofocus
ADVANCEMENTS IN EYE CARE: FATHER-SON TEAM RESTORING SIGHT At the height of the pandemic, across most medical specialties, doctors noted a sharp drop in care as patients curbed nonessential visits and procedures out of the fear that a medical appointment could lead to the coronavirus infection. But it wasn’t just dramatic specialties like cancer or heart care that saw collateral damage from ...
-
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting
ARLINGTON, Mass., May 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported clinical data from a Phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of severe ocular diseases driven ...
-
Notal Vision announces publication of first prospective longitudinal pilot study of daily self-imaging with patient-operated Home OCT in wet AMD patients
Manassas, VA (July 13, 2021) - Notal Vision, Inc. announced today that results from the first prospective longitudinal pilot study of daily, home-based self-imaging with their investigational, patient-operated Home OCT for wet age-related macular degeneration (AMD) patients have been published in Ophthalmology Science.1 The technology is designed to provide retina specialists with remote retinal ...
-
Leo Lens Pharma Expands Its Scientific Advisory Board
SAN DIEGO, CA, USA (Business Wire August 5th, 2020) – Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, announces the expansion of its Scientific Advisory Board (SAB) that now comprises seven world-class eye care professionals, including three ophthalmologists and four optometrists. Leo Lens expanded its SAB with four eye care ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you